Modulating the water solubility and thermal stability of the anti-tuberculosis drug Isoniazid via multicomponent crystal formation

The Benefits and Challenges of Antibiotics-Non-Steroidal Anti-Inflammatory Drugs Non-Covalent Reaction

Recently, non-covalent reactions have emerged as approaches to improve the physicochemical properties of active pharmaceutical ingredients (API), including antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). This review aimed to present and discuss the non-covalent reaction products of antibiotics, including salt and neutral multi-component solid forms, by framing their substituents and molar ratios, manufacturing techniques, characterization methods, benefits, potency changes, and toxicity, and is completed with an analysis of the development of computational models used in this field. Based on the data, NSAIDs are the most-developed drugs in multi-component system preparations, followed by antibiotics, i.e., antituberculosis and fluoroquinolones. They have reacted with inorganic elements, excipients, nutraceuticals, natural products, and other drugs. However, in terms of treatments for common infections, fluoroquinolones are more frequently used. Generally, NSAIDs are acquired on an over-the-counter basis, causing inappropriate medication. In addition, the pKa differences between the two groups of medicine offer the potential for them to react non-covalently. Hence, this review highlights fluoroquinolone-NSAID multi-component solid systems, which offer some benefits. These systems can increase patient compliance and promote the appropriate monitoring of drug usage; the dual drug multi-component solids have been proven to improve the physicochemical properties of one or both components, especially in terms of solubility and stability. In addition, some reports show an enhancement of the antibiotic activity of the products. However, it is important to consider the possibility of activity changes, interaction, and toxicity when using drug combinations. Hence, these aspects also are discussed in this review. Finally, we present computational modeling, which has been utilized broadly to support multi-component system designs, including coformer screening, preparation methods, and structural modeling, as well as to predict physicochemical properties, potency, and toxicity. This integrated review is expected to be useful for further antibiotic-NSAID multi-component system development.

Cocrystals of tuberculosis antibiotics: Challenges and missed opportunities

Cocrystals have been extensively used to improve the physicochemical properties and bioavailability of active pharmaceutical ingredients. Cocrystals of anti-tuberculosis medications are among those commonly reported. This review provides a summary of the tuberculosis antibiotic cocrystals reported in the literature, providing the main results on current tuberculosis medications utilized in cocrystals. Moreover, anti-tuberculosis cocrystals limitations and advantages are described, including evidence for enhanced solubility, stability and effect. Opportunities to enhance anti-tuberculosis medications and fixed dose combinations using cocrystals are given. Several cocrystal pairs are suggested to enhance the effectiveness of anti-tuberculosis drugs.

Development of a purification process via crystallization of xylitol produced for bioprocess using a hemicellulosic hydrolysate from the cashew apple bagasse as feedstock

Xylitol was biotechnologically produced by Kluyveromyces marxianus ATCC36907 using the hemicellulosic hydrolysate of the cashew apple bagasse (CABHH). Sequentially, the present study investigated the recovery and purification of xylitol evaluating different antisolvents [ethanol, isopropanol and the ionic liquid 2-hydroxyl-ethylammonium acetate (2-HEAA)], their proportion in the medium (10-90% v/v), and their cooling rate (V_C 0.25-0.50 °C/min). These processes were contrasted with the crystallization process of commercial xylitol. This study is the first to assess xylitol crystallization using a protic ionic liquid. The hydrolysate obtained from a mild treatment with sulfuric acid contained mainly glucose and xylose at concentrations of 15.7 g/L and 11.9 g/L, respectively. With this bioprocess, a maximum xylitol production of 4.5 g/L was achieved. The performance of the investigated antisolvents was similar in all conditions evaluated in the crystallization process of the commercial xylitol, with no significant difference in yields. For the crystallization processes of the produced xylitol, the best conditions were: 50% (v/v) isopropanol as antisolvent, cooling rate of 0.5 °C/min, with a secondary nucleation of yield and purity of 69.7% and 84.8%, respectively. Under the same linear cooling rate, using ethanol, isopropanol or the protic ionic liquid 2-hydroxyl-ethylammonium acetate (2-HEAA), crystallization did not occur, probably due to the presence of carbohydrates not metabolized by the yeast in the broth, which influences the solubility curve of xylitol. With the results of this work, a possible economical and environmentally friendly process of recovery and purification of xylitol from CABHH could be proposed.

Development of a purification process via crystallization of xylitol produced for bioprocess using a hemicellulosic hydrolysate from the cashew apple bagasse as feedstock

Xylitol was biotechnologically produced by Kluyveromyces marxianus ATCC36907 using the hemicellulosic hydrolysate of the cashew apple bagasse (CABHH). Sequentially, the present study investigated the recovery and purification of xylitol evaluating different antisolvents [ethanol, isopropanol and the ionic liquid 2-hydroxyl-ethylammonium acetate (2-HEAA)], their proportion in the medium (10-90% v/v), and their cooling rate (V_C 0.25-0.50 °C/min). These processes were contrasted with the crystallization process of commercial xylitol. This study is the first to assess xylitol crystallization using a protic ionic liquid. The hydrolysate obtained from a mild treatment with sulfuric acid contained mainly glucose and xylose at concentrations of 15.7 g/L and 11.9 g/L, respectively. With this bioprocess, a maximum xylitol production of 4.5 g/L was achieved. The performance of the investigated antisolvents was similar in all conditions evaluated in the crystallization process of the commercial xylitol, with no significant difference in yields. For the crystallization processes of the produced xylitol, the best conditions were: 50% (v/v) isopropanol as antisolvent, cooling rate of 0.5 °C/min, with a secondary nucleation of yield and purity of 69.7% and 84.8%, respectively. Under the same linear cooling rate, using ethanol, isopropanol or the protic ionic liquid 2-hydroxyl-ethylammonium acetate (2-HEAA), crystallization did not occur, probably due to the presence of carbohydrates not metabolized by the yeast in the broth, which influences the solubility curve of xylitol. With the results of this work, a possible economical and environmentally friendly process of recovery and purification of xylitol from CABHH could be proposed.

Multicomponent crystals of anti-tuberculosis drugs: a mini-review

Tuberculosis (TB) is the leading cause of death from a single infectious agent globally. Some of the early research on TB treatment indicated drug resistance as one of the key challenges in fighting this disease. The discovery that administering two or more drugs simultaneously could lead to much more effective treatment, with reduced drug resistance and shorter periods of chemotherapy, was, therefore, a very significant breakthrough in TB drug research. Pursuant to this discovery, the World Health Organisation (WHO) recommended TB treatment employing fixed-dose combinations (FDCs) containing first line anti-TB drugs; rifampicin, isoniazid, pyrazinamide, streptomycin and ethambutol. Regardless, certain challenges associated with FDCs remain and these include chemical instability and reduced bioavailability of rifampicin. Therefore, some research effort has been directed towards finding ways to deal with these challenges. One such effort involves the use of pharmaceutical co-crystals of the active pharmaceutical ingredients. Consequently, several pharmaceutical co-crystals of isoniazid and pyrazinamide have been reported. This paper aims at reviewing the multicomponent crystal structures of two first-line anti-TB drugs; isoniazid and pyrazinamide. The review will first set out a brief history of the disease, milestones in TB chemotherapy and the challenges associated with current treatment regimens. This will then be followed by a brief introduction to pharmaceutical co-crystals and how they can improve the physical and chemical properties of the active pharmaceutical ingredients. Secondly, multicomponent crystals of the two active pharmaceutical ingredients will be analysed by manual inspection for common supramolecular synthons between the drug molecules as well as between drug molecules and co-formers. Lastly; stability, solubility and dissolution experiments carried out on the pharmaceutical co-crystals of pyrazinamide and isoniazid will be analysed to gain insights into progress made with regards to improving stability and solubility of the active pharmaceutical ingredients.